Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions.
Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, Mehran R, Fahy M, Slack S, Coral M, Teirstein PS, Waksman R, Stone G, Moses J, Leon MB. Costantini CO, et al. Among authors: fahy m. J Am Coll Cardiol. 2003 May 21;41(10):1725-31. doi: 10.1016/s0735-1097(03)00298-5. J Am Coll Cardiol. 2003. PMID: 12767655 Free article. Clinical Trial.
Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation.
Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, Stone GW, Waksman R, Leon MB. Lansky AJ, et al. Among authors: fahy m. J Am Coll Cardiol. 2002 Jan 16;39(2):274-80. doi: 10.1016/s0735-1097(01)01745-4. J Am Coll Cardiol. 2002. PMID: 11788219 Free article. Clinical Trial.
Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial.
Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, Stone G, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB; INHIBIT trial. Costantini CO, et al. Among authors: fahy m. Am J Cardiol. 2003 May 15;91(10):1261-5. doi: 10.1016/s0002-9149(03)00280-7. Am J Cardiol. 2003. PMID: 12745117 Clinical Trial. No abstract available.
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Among authors: fahy m. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R; CADILLAC Investigators. Cox DA, et al. Among authors: fahy m. J Am Coll Cardiol. 2003 Sep 17;42(6):971-7. doi: 10.1016/s0735-1097(03)00911-2. J Am Coll Cardiol. 2003. PMID: 13678914 Free article. Clinical Trial.
228 results